Significant Therapeutic Effects of Anti-Ror1 Car Nk Against Neuroblastoma by Oncolytic Virus Armored With Il-21 In-Vitro and In-Vivo

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2022

DOI

10.1136/jitc-2022-SITC2022.0881

Journal Title

Journal for ImmunoTherapy of Cancer

Department

Pediatrics

Abstract

Background Metastatic and relapsed/refractory neuroblastoma (NB) has very poor diagnosis.1 Novel therapies are desperately needed.2 ROR1 is overexpressed in a variety of human cancers including NB.3-5 Our group has successfully expanded peripheral blood NK cells (exPBNKs) and modified exPBNK cells to express chimeric antigen receptor (CAR).6. Oncolytic herpes simplex viruses (oHSVs) have been safely used in clinical trials for a wide range of cancers.7. IL-21 sustained the survival and increased the cytotoxicity of NK cells.8 We sought to determine the anti-tumor effect of anti-ROR1 CAR engineered exPBNK cells (CAR-exPBNKs) against ROR1+ NB and if the anti-tumor efficacy can be improved by oHSV engineered to express human IL21. Methods NK cells were expanded and electroporated with anti-ROR1-CAR mRNA. oHSV C134 was modified to express hIL-21 gene (C021). In-vitro cytotoxicity and cytokines levels of CAR-exPBNKs against NB cell lines were examined as we previously described (2). In-vivo hIL21 secretion and antitumor effect of CAR-exPBNKs with or without the C021 was examined utilizing human NB xenografted NSG mice. Results NK cells were significantly expanded by co-culture with irradiated K562-mbIL21 cells at 14 days (>2000 folds), and expanded NK cells were isolated with more than 95% purity. Anti-ROR1-CAR was expressed on >90% of exPBNK cells after CAR mRNA electroporation. CAR-exPBNK cells had significantly enhanced in-vitro cytotoxicity compared to Mock-exPBNK against ROR1+ SKNBE(2)N, CHLA-255, and SKNFI NB cells at different E:T ratios (p<0.001) regardless of MYCN amplification status. Expression of CD107a and IFN-γ were significantly increased in CAR-exPBNK cells compared to Mock-exPBNK (p<0.05). CyTOF analysis showed that phosphorylation of STAT5 was enhanced in CARexPBNK when targeting NB as compared to exPBNK cells. In-vivo study showed that CAR-exPBNK significantly extended mice survival in human NB xenografted NSG mice (p<0.01) (figure 1). Furthermore, the combination of C021 and CARexPBNK significantly enhanced the killing of NB with significantly enhanced secretion of IFN-g, granzyme B and perforin and significantly enhanced expression of NK activating marker CD25 (all p<0.05) compared to controls. Our in-vivo animal study showed that NB infected with C021 secreted hIL21 and the combination of C021 and CAR-exPBNK cells reduced tumor burden in human NB xenografted NSG mice compared to the untreated group (p<0.05) and the CAR exPBNKstreated group (P=0.056) (figure 2). Conclusions Our data demonstrate the significant anti-tumor efficacy of combining C021 with anti-ROR1 CAR-exPBNKs to therapeutically target NB in-vitro and in-vivo. (Figure Presented).

This document is currently not available here.

Share

COinS